Tag: bioequivalence issues

Deficiency Letters in Generic Applications: Common FDA Findings Explained 3 July 2026

Deficiency Letters in Generic Applications: Common FDA Findings Explained

Explore common FDA deficiency letters in generic drug applications. Learn about top findings in ANDA reviews, including dissolution issues, impurities, and bioequivalence challenges, and how to avoid them.